NL-OMON37899招募中不适用
Midazolam as a potential CYP3A phenotyping probe for cabazitaxel metabolism. - MAILMAN-study
Meander Medisch Centrum0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Metastasized hormone refractory prostate cancer.
- •Progression of disease during or after treatment with docetaxel.
排除标准
- •Severe dyspnea
- •Myasthenia Gravis
- •Sleep apnea syndrome.
- •Severe hepatic dysfunction
- •Age 80 years and older
研究者
相似试验
招募中
不适用
Observational Study;Midazolam as CYP3A phenotyping probe to investigate the effects of lapatinib on hepatic CYP3A activity.1. cancer<br />2. drug-drug interaction<br />3. CYP3A<br />4. lapatinib.NL-OMON22273Erasmus MC-Daniel den HoedDepartment of Medical OncologyGroene Hilledijk 3013075 EA Rotterdamthe Netherlands15
已完成
不适用
Pharmacokinetics of the CYP3A substrate Midazolam after steady-state dosing of IMU-935.Chronic inflammatory diseasesautoimmune and chronic inflammatory diseasescastration-resistant prostate cancer1000381610036958NL-OMON51575Immunic AG16
终止
1 期
A Tasisulam and Midazolam Drug Interaction Study in Cancer PatientsAdvanced CancerNCT01209832Eli Lilly and Company11
已完成
1 期
A Study of LY2623091 in Healthy ParticipantsHealthy VolunteersNCT02300259Eli Lilly and Company48
已完成
不适用
In vivo CYP3A activity in palliative care patientsIn vivo CYP3A activity in palliative care patientsDRKS00011753niversitätsklinikum Heidelberg, Klinik für Anäthesiologie41